Q4 2026
Nov 15, 2026
Digi shares fell 10.2% after earnings, pointing to investor concern despite management’s report of records and results generally above its guidance. The transcript provided does not identify a specific miss or explain the selloff, so the likely disappointment cannot be pinned to a particular metric or outlook driver.
Key takeaways
- Management said the company posted record quarterly revenue, ARR and adjusted EBITDA, and that results were above guidance “almost across the board.”
- ARR was ahead of management’s target; the company did not provide the actual ARR figure in the portion of the call provided.
- Digi said it devotes about 15% of revenue to innovation, including work on AI applications at the edge and in the cloud.
- Management said it integrated Jolt and Particle into common systems and processes and achieved its financial objectives; it described the Disruptive Technologies acquisition as its next integration priority.
- The transcript provided ends before detailed financial results or guidance figures are discussed, limiting assessment of the factors behind the share-price decline.
Q3 2026
Aug 10, 2026
Shares rallied 15.1% following a quarter marked by strong revenue growth and margin expansion that outpaced prior expectations, alongside an upward revision to full-year guidance.
Key takeaways
- Q3 revenue reached $139 million, up 29% year-over-year, demonstrating solid top-line momentum.
- Gross margins expanded to 64.8%, supporting a robust adjusted EBITDA margin of 29.1% and $40 million in adjusted EBITDA.
- Cash flow from operations increased 38% year-over-year to $33 million, now exceeding the year-to-date adjusted EBITDA on an annualized basis.
- Annual recurring revenue (ARR) hit a record of $191 million, with management projecting at least 27% ARR growth for the full year.
- Q4 guidance was raised to $138–142 million in revenue and $40–41.5 million in adjusted EBITDA, lifting full-year revenue guidance to $529–533 million and adjusted EBITDA to $146–147.5 million, reflecting accelerating profitable growth.
Q2 2026
May 9, 2026
Biote’s shares gained 11.8% following a quarter marked by a voluntary product recall that disrupted sales but highlighted progress in commercial expansion and practitioner engagement, suggesting improving fundamentals despite near-term headwinds.
Key takeaways
- Revenue declined 8.3% to $44.9 million, with procedure revenue down 13.2%, partly due to a $1.7 million impact from a voluntary hormone pellet recall.
- The recall also caused approximately $1.5 million in incremental costs and distracted the sales force from growth initiatives.
- Biote expanded its sales team substantially, adding over 25 new sales personnel in Q1 2026, now nearing the targeted 120 total.
- Training of new practitioners increased 16.5% year-over-year, signaling strong future growth potential given typical six-month lag to contribution.
- Management emphasized a more disciplined sales pipeline focus on higher-value OB/GYN and general practitioners, aiming for more predictable revenue streams.
Q1 2026
Feb 5, 2026
Digi International Inc. reported a robust first quarter of fiscal 2026, achieving record revenues of $122 million, marking an 18% increase year over year, while successfully integrating the acquisition of Particle, contributing to strong annualized recurring revenue (ARR) growth.
Key takeaways
- Quarterly revenues reached $122 million, up 18% year-over-year, with annualized recurring revenue growing 31% to $157 million.
- Adjusted EBITDA was $32 million, a 23% increase year over year, with a record margin of 25.8%.
- Integration of Particle enhances Digi's IoT capabilities, contributing $20 million in ARR and reinforcing the company's market position.
- Digi's operational guidance forecasts ARR growth of 23% and revenue growth of 14% to 18% for fiscal 2026.
- The company is positioned to leverage AI advancements in its product offerings, further enhancing its competitive landscape.